** Shares of Acadia Pharmaceuticals fall 5.4% to $15.42
** California-based biopharmaceutical company appoints Catherine Owen Adams as new CEO
** Previously, Adams was senior vice president and general manager, U.S., at Bristol Myers Squibb
** Adams succeeds Steve Davis, company's CEO since Sept. 2015
** Thirteen of 19 brokerages rate stock "buy" or higher, 5 rate "hold" and one "sell"; their median PT is $26.5
** Including session's losses, stock down more than 50% YTD
(Reporting by Sukriti Gupta)
((Sukriti.Gupta@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.